The present disclosure provides inhibitors of microorganisms including viruses and fungi of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of treatment using these agents in the treatment of infections of microorganisms such as viruses and fungi.

##STR00001##

[Problem] To provide novel anti-tumor agents and combination drugs.

[Means to solve] To provide an anti-tumor agent containing, as an active ingredient, a glutathione level reducer or a glutathione S-transferase inhibitor, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a compound (II); an anti-tumor agent including a compound (II) as an active ingredient, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a glutathione level reducer or a glutathione S-transferase inhibitor; or an anti-tumor agent containing, as active ingredients, a compound (II) and a glutathione level reducer or a glutathione S-transferase inhibitor, where R.sup.5 is a linear or branched C1-6 alkyl group, R.sup.6 is hydrogen or halogen, R.sup.7 is a linear or branched C1-6 alkyl group optionally substituted with a substituent, the substituent being hydroxy or phenyl, and R.sup.8 is hydrogen or halogen.

[Problem] To provide novel anti-tumor agents and combination drugs.

[Means to solve] To provide an anti-tumor agent containing, as an active ingredient, a glutathione level reducer or a glutathione S-transferase inhibitor, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a compound (II); an anti-tumor agent including a compound (II) as an active ingredient, the anti-tumor agent being adapted to be administered simultaneously with an effective amount of a glutathione level reducer or a glutathione S-transferase inhibitor; or an anti-tumor agent containing, as active ingredients, a compound (II) and a glutathione level reducer or a glutathione S-transferase inhibitor, where R.sup.5 is a linear or branched C1-6 alkyl group, R.sup.6 is hydrogen or halogen, R.sup.7 is a linear or branched C1-6 alkyl group optionally substituted with a substituent, the substituent being hydroxy or phenyl, and R.sup.8 is hydrogen or halogen.

The present invention relates to the process and therapeutic use of endocannabinoid-targeting novel prodrugs in a delivery system. In particular, the present invention relates to prodrugs of endocannabinoid system-targeting molecules, as cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabinol (THC), and cannabichromene (CBC) for oral, transmucosal, transdermal, and parenteral administration, and methods and using the same as therapeutics.

The present invention relates to the process and therapeutic use of endocannabinoid-targeting novel prodrugs in a delivery system. In particular, the present invention relates to prodrugs of endocannabinoid system-targeting molecules, as cannabidiol (CBD), cannabigerol (CBG), tetrahydrocannabinol (THC), and cannabichromene (CBC) for oral, transmucosal, transdermal, and parenteral administration, and methods and using the same as therapeutics.

The invention relates to a gel-chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the gel-chewable dosage form and wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the gel-chewable dosage form.

The invention relates to a gel-chewable dosage form comprising a first active pharmaceutical ingredient encapsulated in a lipid material that is embedded in the gel-chewable dosage form and wherein the gel-chewable dosage form comprises at least a second active pharmaceutical ingredient as well as a method of treating a subject suffering from a disease or disorder in the gastro intestinal tract using the gel-chewable dosage form.

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.

Compounds, and compositions, methods, and uses thereof, are described herein for treating neurodegenerative diseases and disorders. In particular, vasopressin receptor modulators, and compositions, methods and uses thereof, are described herein for treating neuropsychiatric aspects of neurodegenerative diseases such as Huntington's Disease, Parkinson's Disease, and Alzheimer's Disease.

The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (I): ##STR00001##
wherein: R.sub.1 is H, —OMe, Me, or one or more electron withdrawing groups; R.sub.2 and R.sub.3 are each independently H or alkyl or, taken together, form a 4- to 8-membered heterocyclic ring with the adjacent nitrogen atom; R.sub.4 is H or alkyl; R.sub.5 is H or one or more electron donating groups; and n is 1 to 4.